R E Brown

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. ncbi Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
    R E Brown
    UBC Health Care Analytics Group, London, UK
    Curr Med Res Opin 22:663-70. 2006
  2. ncbi Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK
    E Remak
    The MEDTAP Institute at UBC, London, UK
    Curr Med Res Opin 21:1505-17. 2005
  3. ncbi Cost effectiveness of treatment options in advanced breast cancer in the UK
    R E Brown
    MEDTAP International, Inc, London, UK
    Pharmacoeconomics 19:1091-102. 2001
  4. ncbi Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy
    R E Brown
    MEDTAP International Inc, London, U.K
    Eur Heart J 23:50-8. 2002

Collaborators

Detail Information

Publications4

  1. ncbi Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
    R E Brown
    UBC Health Care Analytics Group, London, UK
    Curr Med Res Opin 22:663-70. 2006
    ..This study estimates the annual 2003 expenditures in the UK for CC screening, follow-up of abnormal findings, CC treatment and GW treatment...
  2. ncbi Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK
    E Remak
    The MEDTAP Institute at UBC, London, UK
    Curr Med Res Opin 21:1505-17. 2005
    ....
  3. ncbi Cost effectiveness of treatment options in advanced breast cancer in the UK
    R E Brown
    MEDTAP International, Inc, London, UK
    Pharmacoeconomics 19:1091-102. 2001
    ..Even in the worst case scenarios, docetaxel remained cost effective compared with paclitaxel and vinorelbine. CONCLUSIONS: These findings support the use of the taxoids, notably docetaxel, in the management of advanced breast cancer...
  4. ncbi Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy
    R E Brown
    MEDTAP International Inc, London, U.K
    Eur Heart J 23:50-8. 2002
    ..Long-term projections indicate a modest increase in survival in eptifibatide patients. These data translate into cost-effectiveness ratios that compare favourably with other new technologies that are currently in use...